Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PALIVIZUMAB Cause Product dose omission issue? 381 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 381 reports of Product dose omission issue have been filed in association with PALIVIZUMAB (Synagis). This represents 3.3% of all adverse event reports for PALIVIZUMAB.

381
Reports of Product dose omission issue with PALIVIZUMAB
3.3%
of all PALIVIZUMAB reports
4
Deaths
123
Hospitalizations

How Dangerous Is Product dose omission issue From PALIVIZUMAB?

Of the 381 reports, 4 (1.0%) resulted in death, 123 (32.3%) required hospitalization, and 2 (0.5%) were considered life-threatening.

Is Product dose omission issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PALIVIZUMAB. However, 381 reports have been filed with the FAERS database.

What Other Side Effects Does PALIVIZUMAB Cause?

Respiratory syncytial virus infection (1,692) Pyrexia (1,055) Death (856) Bronchiolitis (724) Cough (665) Pneumonia (657) Dyspnoea (466) Nasopharyngitis (462) Vomiting (445) Influenza (398)

What Other Drugs Cause Product dose omission issue?

DUPILUMAB (18,189) USTEKINUMAB (9,405) GUSELKUMAB (9,267) LENALIDOMIDE (8,145) MEPOLIZUMAB (5,873) TOFACITINIB (5,646) VOXELOTOR (5,122) BELIMUMAB (4,671) SECUKINUMAB (4,572) APREMILAST (4,460)

Which PALIVIZUMAB Alternatives Have Lower Product dose omission issue Risk?

PALIVIZUMAB vs PALONOSETRON PALIVIZUMAB vs PAMIDRONATE PALIVIZUMAB vs PAMIDRONIC ACID PALIVIZUMAB vs PANCRELIPASE PALIVIZUMAB vs PANCRELIPASE AMYLASE\PANCRELIPASE LIPASE\PANCRELIPASE PROTEASE

Related Pages

PALIVIZUMAB Full Profile All Product dose omission issue Reports All Drugs Causing Product dose omission issue PALIVIZUMAB Demographics